Microfluidic in-vitro blood brain barrier model and use method thereof

Through the modular assembly technology of microfluidic chips and hydrogels, a high-fidelity blood-brain barrier model was built, solving the problem of insufficient accuracy and complexity of the existing models, and achieving more accurate verification of drug delivery mechanisms and simplicity of operation provide an important foundation for drug development in neurological diseases.

CN119060847APending Publication Date: 2024-12-03ZHEJIANG UNIV OF TECH
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202411326696.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing in vitro blood-brain barrier model has insufficient accuracy and complexity in simulating the function of the human blood-brain barrier, especially the lack of complexity and physiological shear stress of human brain tissue, resulting in low accuracy in drug delivery mechanism verification, and The microfluidic model has problems with insufficient structure and uneven flow.

Method used

Using microfluidic chip combined with hydrogel modular assembly, a high-fidelity blood-brain barrier model is constructed through hydrogel carrying mouse brain microvascular endothelial cells and astrocytes, and a microinjection circulating pump is used to simulate the blood-brain barrier in vivo Artificial cerebrospinal fluid and blood can achieve contact coculture and rapid optimization.

Benefits of technology

Eliminates species differences, the experimental data obtained are in line with the real situation of the human body, improves the accuracy and simplicity of the blood-brain barrier model, provides a theoretical basis for the clinical transformation of the brain-targeted drug delivery system, and has a good commercial value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060847A_ABST
    Figure CN119060847A_ABST
Patent Text Reader

Abstract

The invention discloses a microfluidic in-vitro blood brain barrier model and a use method thereof. Comprising a micro-fluidic chip, a glass bottom plate, hydrogel and a micro-injection circulating pump, wherein the micro-fluidic chip is made on the basis of a polydimethylsiloxane material; the micro-fluidic chip comprises a first channel, a second channel and a third channel; the hydrogel comprises hydrogel loaded with mouse brain microvascular endothelial cells and hydrogel loaded with mouse astrocytes; the micro-injection circulating pump is used for filling artificial cerebrospinal fluid and artificially synthesized blood so as to simulate the operation of the cerebrospinal fluid and the blood on the two sides of the blood brain barrier in the body. According to the invention, the cell activity, TEER value and permeability in the model are detected, and a cell-loaded hydrogel replacement method is adopted, so that optimization of parameters of the integrated microfluidic chip is rapidly realized, and a high-fidelity hydrogel microfluidic BBB model is constructed according to different disease conditions. The method has the advantages of being easy and convenient to operate and easy to popularize on the premise that effectiveness and accuracy are guaranteed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of tissue engineering and biomanufacturing technology under biomedical engineering, and specifically relates to a microfluidic in vitro blood-brain barrier model and a method for using the same. Background Art

[0002] The blood-brain barrier is a special biological interface between the blood circulation and the nervous tissue. As a highly selective semi-permeable biological barrier, it plays an important role in the normal conduct of physiological activities. The blood-brain barrier is responsible for controlling the transport of molecules and ions, acting as an interface between the peripheral blood circulation and the central nervous system. Transporters and tight junctions (TJs) regulate the passage of nutrients while protecting the brain from toxins and pathogens. The main components of the blood-brain barrier are tightly connected brain microvessel endothelial cells (BMECs), basement membranes, and a variety of other supporting cells embedded in the basement membrane (such as pericytes, astrocytes, microglia, etc.). In addition to the complex cell network and tight junctions between cells, a variety of proteins related to cell tight junctions are also highly expressed on the surface of these cells, such as occludin, claudin family, zonula occludens (ZO) family, etc. These together enable the blood-brain barrier to separate the brain parenchyma from the systemic blood circulation at the microvascular level, providing a structural support for the formation of the biological barrier.

[0003] The blood-brain barrier prevents most macromolecular drugs and about 98% of small molecule drugs from entering the brain to maintain the homeostasis of the central nervous system. It is easy for fat-soluble substances, O2, CO2 and certain anesthetics to pass through, but the permeability to water-soluble substances varies greatly. For example, it has high permeability to glucose and amino acids, but very low permeability to mannitol, sucrose and certain ions, or even cannot pass through. In many cases, in vivo animal models are generally used to verify whether drugs can pass through the BBB, but due to the inevitable species differences between small animals and humans, the accuracy of the blood-brain barrier model is difficult to guarantee. Therefore, the development and in-depth research of in vitro blood-brain barrier models will provide an important theoretical basis for drug development and disease diagnosis and treatment of neurological diseases.

[0004] Compared with animal models, in vitro blood-brain barrier models have lower costs, better stability, and can achieve more intuitive detection, which is conducive to the exploration of drug delivery mechanisms. Although the cell-based Transwell model is also widely used, it lacks the complexity of human brain tissue (including the lack of physiological shear stress and the difficulty of cells to maintain BBB characteristics), and the accuracy of verifying the in vivo process of drugs is low. Microfluidic chip systems have gradually become an ideal technical platform for constructing in vitro blood-brain barrier models due to their miniaturization, integration, high throughput and easy cell manipulation. Its design is mainly divided into four categories: sandwich design, parallel design, three-dimensional tubular design and angiogenesis design. However, it has disadvantages. For example, the effective area of ​​cell co-culture in the sandwich design structure is larger, which is suitable for drug screening but cannot achieve contact co-culture; the three-dimensional tubular design will lead to uneven flow and shear stress distribution, resulting in differences in the morphology of cells along the rectangular channel. In order to better make up for the shortcomings of the current microfluidic model, it is particularly important to develop a new and efficient BBB model. Hydrogels have the characteristics of high water content, adjustable mechanical properties, high similarity to natural ECM, and the ability to adhere to and maintain cell behavior. The use of hydrogels allows cells to grow in a three-dimensional environment and has appropriate mechanical, biophysical, and biochemical properties to better replicate the in vivo structure of natural tissues. Therefore, it is of great significance to develop an efficient in vitro blood-brain barrier model based on hydrogels that can achieve contact co-culture while being simple to operate, easy to detect, and can be rapidly optimized. Summary of the invention

[0005] In view of the deficiencies of the prior art, an object of the present invention is to provide a microfluidic in vitro blood-brain barrier model and a method for using the same.

[0006] The objective of the present invention is achieved through the following technical scheme: a microfluidic in vitro blood-brain barrier model, comprising: a microfluidic chip, a glass bottom plate, a hydrogel and a microinjection circulation pump; the microfluidic chip is arranged on the glass bottom plate, the microfluidic chip comprises a first channel, a second channel and a third channel, and the channels are separated by a first PDMS column and a second PDMS column; the microfluidic chip is separated by a PDMS separator column and is divided into three parts with the same structure; the hydrogel comprises a hydrogel carrying mouse brain microvascular endothelial cells (bEnd.3) and a hydrogel carrying mouse astrocytes (MA); the microinjection circulation pump is used to perfuse artificial cerebrospinal fluid and artificial synthetic blood that simulate the blood-brain barrier in vivo.

[0007] Furthermore, the hydrogel carrying mouse brain microvascular endothelial cells includes GelMA, GelMA-PEGDA, and GelMA-HAMA hydrogels carrying mouse brain microvascular endothelial cells; the mouse astrocytes include GelMA, GelMA-PEGDA, and GelMA-HAMA hydrogels carrying mouse astrocytes.

[0008] Furthermore, the hydrogels are synthesized by UV curing and cross-linking, the curing time is 5-10 minutes, the photoinitiators are Irgacure2959 and LAP, the concentration of the photoinitiator is 0.2%-0.5% (photoinitiator mg: PBS solution mL), the illumination time is 5-10 minutes, the illumination height is 5-20 cm, the UV lamp power is 20-30 W, and finally the thickness of the obtained hydrogel sheet is controlled to be 1-2 mm; wherein the UV curing band is 405 nm.

[0009] Furthermore, the GelMA, GelMA-PEGDA, and GelMA-HAMA hydrogels are prepared by the following method:

[0010] GelMA hydrogels were prepared by using different feed ratios of MAA: gelatin = 0.1-0.5:1 (mL:g) according to the different grafting of methacrylic anhydride MAA. The MAA grafting rate of the obtained hydrogels ranged from 50.5% to 68%. The swelling rate of GelMA hydrogels with different grafting rates ranged from 473.8% to 732.6%, the compressive strength ranged from 15.37% to 76.99Kpa, and the elastic modulus ranged from 93.24% to 434.8Kpa.

[0011] In the GelMA precursor material, PEGDA is added to obtain a GelMA-PEGDA hydrogel, wherein the ratio of PEGDA added is 1-5% (PEGDA g / PBS solution mL); the swelling ratio of the GelMA-PEGDA hydrogel is in the range of 551.8-734.2%, the compression strength is in the range of 11.02-102.5 KPa, and the elastic modulus is in the range of 56.73-489.2 KPa;

[0012] By adding HAMA to the GelMA precursor material, GelMA-HAMA hydrogel is obtained, wherein the proportion of HAMA added is 1-2% (HAMA g / PBS solution mL); the swelling rate of GelMA-HAMA hydrogel ranges from 642.2 to 865.3%, the compression strength ranges from 31.35 to 47.6 KPa, and the elastic modulus ranges from 124.5 to 209.9 KPa.

[0013] Furthermore, the microfluidic chip package is divided into a first channel, a second channel and a third channel in sequence; the first channel is used for perfusing cerebrospinal fluid, the second channel is used for placing a cell-laden hydrogel sheet, and the third channel is used for perfusing artificial synthetic blood; the second channel is provided with a groove for fixing the hydrogel sheet, the groove being separated by a first PDMS column, dividing the groove into two parts, so that the initial fixed position of the hydrogel sheet in the groove will not move after the subsequent introduction of artificial synthetic blood and artificial cerebrospinal fluid; the hydrogel carrying mouse brain microvascular endothelial cells is placed in the groove close to the third channel, and the hydrogel carrying mouse astrocytes is placed in the groove close to the first channel.

[0014] Furthermore, the glass bottom plate is 64 mm long, 34 mm wide and 4 mm high; the chip is 46 mm long, 24 mm wide and 6 mm high; the first PDMS column is 2.4 mm long, 1 mm wide, 0.3 mm apart and 3 mm high; the second PDMS column is 0.3 mm long, 1 mm wide and 1 mm high; the first channel is 46 mm long, 6.5 mm wide and 4 mm deep; the two parts of the second channel groove are the same, 14 mm long, 3 mm wide and 3 mm high, so that the hydrogel sheet fits better with the chip model and will not overturn under the action of fluid shear stress; the third channel is 46 mm long, 8.5 mm wide and 4 mm deep; the PDMS separator column is 15.9 mm long, 6.5 mm wide and 2.8 mm high, and its height is smaller than the groove of the cell-carrying hydrogel sheet, which is convenient for fixing the hydrogel sheet in the groove.

[0015] The present invention also provides a method for using a microfluidic in vitro blood-brain barrier model, comprising the following steps:

[0016] GelMA, GelMA-PEGDA, and GelMA-HAMA hydrogels were co-cultured with mouse brain microvascular endothelial cell hydrogels and astrocytes; the initial amount of the two cells co-cultured with the hydrogels was 5×10 5 -4×10 6 cells / mL, and the co-culture time of the two cells with the hydrogel was 1-5 days;

[0017] The hydrogels carrying mouse brain microvascular endothelial cells and the hydrogels carrying astrocytes are placed in corresponding hydrogel channels; when the hydrogel sheets form a microfluidic BBB model, the same type of hydrogel sheets are selected to place the hydrogel sheets carrying mouse brain microvascular endothelial cells and the hydrogel sheets carrying astrocytes, or two different types of hydrogel sheets are selected to place the hydrogel sheets carrying mouse brain microvascular endothelial cells and the hydrogel sheets carrying astrocytes;

[0018] Use a microinjection circulation pump to introduce artificial synthetic blood at a flow rate of 100-300 μL / min, and artificial cerebrospinal fluid at a flow rate of 10-20 μL / min;

[0019] After the artificial synthetic blood and artificial cerebrospinal fluid circulate in the microfluidic chip for 3-5 hours, the TEER value is measured; FITC-dextran (molecular weight 4KDa) is introduced into the synthetic blood channel, and the fluorescence intensity of the blood channel and the artificial cerebrospinal fluid channel is measured 4-5 hours later to verify the permeability of FITC-dextran.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] 1. The blood-brain barrier model of the present invention eliminates species differences compared to the blood-brain barrier animal model in vivo, and the experimental data obtained through the blood-brain barrier model is consistent with the actual situation of the human body. In addition, this platform combines the microfluidic chip with the cell-carrying hydrogel to form a hydrogel modular assembly (detachable and replaceable)-microfluidic BBB model, thereby constructing a high-fidelity hydrogel microfluidic BBB model, providing a theoretical basis for exploring the rapid clinical transformation of new brain-targeted drug delivery systems.

[0022] 2. The blood-brain barrier model of the present invention has the characteristics of simple operation and easy promotion while ensuring the effectiveness and accuracy of the blood-brain barrier model, and has good commercial value.

[0023] In summary, the in vitro blood-brain barrier model with a tight junction structure constructed by the present invention can well simulate the function of the human blood-brain barrier, improve the accuracy and effectiveness of blood-brain barrier drug research and development, and is simple to operate and easy to promote, providing an important research basis for the development of drugs for nervous system diseases and disease diagnosis and treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a plan design of the microfluidic in vitro blood-brain barrier model;

[0025] Figure 2 Summary of TEER values ​​of microfluidic in vitro blood-brain barrier model measured using different types of hydrogels;

[0026] Figure 3 Summary of the permeability of 4KDa FITC-dextran in a microfluidic in vitro blood-brain barrier model measured using different types of hydrogels;

[0027] Figure 4Figure 2 is the live and dead cell staining data of GelMA hydrogels with different feed ratios; (a) is the live and dead cell staining diagram of GelMA hydrogel prepared with feed ratio MAA: gelatin = 0.1:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days, (b) is the live and dead cell staining diagram of GelMA hydrogel prepared with feed ratio MAA: gelatin = 0.25:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days, (c) is the live and dead cell staining diagram of GelMA hydrogel prepared with feed ratio MAA: gelatin = 0.5:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days, (d) is the live and dead cell staining diagram of GelMA hydrogels with three different feed ratios and bEnd .3 Quantitative analysis of live and dead cell staining after 5 days of cell co-culture, (e) is the live and dead cell staining of GelMA hydrogel prepared with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and MA cells after 5 days of co-culture, (f) is the live and dead cell staining of GelMA hydrogel prepared with a feed ratio of MAA: gelatin = 0.25:1 (mL:g) and MA cells after 5 days of co-culture, (g) is the live and dead cell staining of GelMA hydrogel prepared with a feed ratio of MAA: gelatin = 0.5:1 (mL:g) and MA cells after 5 days of co-culture, (h) is the quantitative analysis of live and dead cell staining of GelMA hydrogels with three different feed ratios after 5 days of co-culture with MA cells;

[0028] Figure 5Figure 2 is a live and dead cell staining data of GelMA-PEGDA hydrogel; wherein, (a) is a live and dead cell staining diagram of GelMA-1% PEGDA hydrogel prepared by adding 1% PEGDA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days, (b) is a live and dead cell staining diagram of GelMA-3% PEGDA hydrogel prepared by adding 3% PEGDA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days, (c) is a live and dead cell staining diagram of GelMA-5% PEGDA hydrogel prepared by adding 5% PEGDA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days, (d) is a live and dead cell staining diagram of the above three GelMA-PEGDA hydrogels with bEn d.3 Quantitative analysis of live and dead cell staining after 5 days of co-culture of cells, (e) is a live and dead cell staining diagram of GelMA-1% PEGDA hydrogel prepared by adding 1% PEGDA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and MA cells after 5 days of co-culture, (f) is a live and dead cell staining diagram of GelMA-3% PEGDA hydrogel prepared by adding 3% PEGDA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and MA cells after 5 days of co-culture, (g) is a live and dead cell staining diagram of GelMA-5% PEGDA hydrogel prepared by adding 5% PEGDA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and MA cells after 5 days of co-culture, (h) is a quantitative analysis of live and dead cell staining of the above three types of GelMA-PEGDA hydrogels after 5 days of co-culture with MA cells;

[0029] Figure 6Figures 2 and 3 are data graphs of live and dead cell staining of GelMA-HAMA hydrogels; wherein (a) is a live and dead cell staining graph of GelMA-1% HAMA hydrogel prepared by adding 1% HAMA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days; (b) is a live and dead cell staining graph of GelMA-2% HAMA hydrogel prepared by adding 2% HAMA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and co-cultured with bEnd.3 cells for 5 days; (c) is a live and dead cell staining graph of the above two GelMA-HAMA hydrogels co-cultured with bEnd.3 cells. Quantitative analysis of live and dead cell staining after 5 days of culture, (d) is a live and dead cell staining diagram of GelMA-1% HAMA hydrogel prepared by adding 1% HAMA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and co-cultured with bEnd.3MA cells for 5 days, (e) is a live and dead cell staining diagram of GelMA-2% HAMA hydrogel prepared by adding 2% HAMA to GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g) and co-cultured with MA cells for 5 days, (f) is a quantitative analysis of live and dead cell staining of the above two types of GelMA-HAMA hydrogels after co-culture with MA cells for 5 days;

[0030] Figure 7 This is a structural diagram of the microfluidic in vitro blood-brain barrier model. DETAILED DESCRIPTION

[0031] The present invention is described in detail below in conjunction with the accompanying drawings. In the absence of conflict, the features of the following embodiments and implementations can be combined with each other.

[0032] (1) Design of microfluidic in vitro blood-brain barrier model:

[0033] like Figure 1 and Figure 7As shown, the microfluidic in vitro BBB model includes a glass bottom plate and a PDMS (polydimethylsiloxane) chip; wherein the glass bottom plate is 64 mm long, 34 mm wide, and 4 mm high; the PDMS chip is 46 mm long, 24 mm wide, and 6 mm high. The PDMS chip consists of three channels, namely the first channel, the second channel, and the third channel, wherein the first channel is used to perfuse cerebrospinal fluid, the second channel is used to place a cell-carrying hydrogel sheet, and the third channel is used to perfuse artificial synthetic blood; the three channels are separated by a first PDMS column and a second PDMS column, wherein the first PDMS column is 2.4 mm long, 1 mm wide, 0.3 mm apart, and 3 mm high; a second PDMS column is provided in the interval of the first PDMS column, and the second PDMS column is 0.3 mm long, 1 mm wide, and 1 mm high. Among these three parts, the third channel for perfusing artificial synthetic blood is 46mm long, 8.5mm wide and 4mm deep; the first channel for perfusing cerebrospinal fluid is 46mm long, 6.5mm wide and 4mm deep; the groove of the second channel for placing the cell-carrying hydrogel sheet is separated by the first PDMS column and divided into two parts, both of which are 14mm long, 3mm wide and 3mm high. The PDMS chip is separated by a PDMS separator column and divided into three parts with the same structure. The PDMS separator column is 15.9mm long, 6.5mm wide and 2.8mm high, and the height is smaller than the groove of the cell-carrying hydrogel sheet, which is convenient for fixing the hydrogel sheet in the groove and maintaining the original placement state under the shear force of the fluid flow. It will not overturn. The hydrogels carrying different cells are separated by the first PDMS column and the second PDMS column. On the one hand, it helps the hydrogel sheet to maintain the state when it is initially placed in the groove during the experiment, and when artificial blood and artificial cerebrospinal fluid are synthesized, the fluid shear stress generated by them can be moved or overturned; on the other hand, in order to more accurately simulate the BBB in the body, two hydrogel sheets carrying different cells are distinguished, and the hydrogel sheet carrying mouse brain microvascular endothelial cells (bEnd.3) is close to the blood, and the astrocyte (MA) hydrogel sheet is close to the cerebrospinal fluid. The size of the groove for placing the hydrogel sheet is designed according to the size of the hydrogel sheet made. The size of the hydrogel sheet used in the present invention is 14mm long, 3mm wide, 1mm thick, and 14mm long, 3mm wide, 2mm thick, so a groove with a depth and width of 3mm is used, so that the hydrogel sheet and the chip model are well fitted, and the phenomenon of overturning will not occur under the action of fluid shear stress.

[0034] (2) Preparation and characterization of three hydrogels: GelMA, GelMA-PEGDA and GelMA-HAMA:

[0035] According to the different MAA grafting rates, the MAA grafting rates of the GelMA hydrogel prepolymer prepared by using different feed ratios of MAA: gelatin = 0.1-0.5: 1 (mL: g) range from 50.5 to 68%. The GelMA hydrogel prepolymer and the photoinitiator (LAP) were placed in a centrifuge tube and fully dissolved in a 37°C constant temperature water bath, wherein the GelMA hydrogel prepolymer: PBS solution = 200-300 mg: 2-3 mL; LAP: PBS solution = 2-6 mg: 2-3 mL. The dissolved solution is measured and injected into a rectangular mold with a length of 12-15 mm, a width of 2-5 mm, and a height of 1-2 mm. The hydrogel precursor solution is injected into the mold and irradiated with 405 nm ultraviolet light for 5-10 min, and the illumination height is 5-20 cm. LAP is excited by 405 nm ultraviolet light to rearrange molecules and form free radical intermediates. The free radicals react with carbon-carbon double bonds to cause free radical polymerization, and finally form a stable hydrogel polymer. The swelling rate and compression strength of GelMA hydrogel are tested respectively (the instrument used is a universal material testing machine). The results obtained are that the swelling rate of GelMA hydrogels with different grafting rates ranges from 473.8 to 732.6%, the compression strength ranges from 15.37 to 76.99 Kpa, and the elastic modulus ranges from 93.24 to 434.8 Kpa.

[0036] The preparation process of GelMA-PEGDA hydrogel is similar to that of the above-mentioned GelMA hydrogel. On the basis of the prepared GelMA hydrogel prepolymer, PEGDA is added to obtain GelMA-PEGDA hydrogel, wherein the ratio of PEGDA added is 1-5% (PEGDA mg: PBS solution mL). Specifically, GelMA hydrogel prepolymer: PBS solution = 200-300 mg: 2-3 mL; LAP: PBS solution = 2-6 mg: 2-3 mL; PEGDA: PBS solution = 20-100 mg: 2-3 mL. The swelling rate and compressive strength of GelMA-PEGDA hydrogel were then tested respectively, and the results obtained were that the swelling rate of GelMA-PEGDA hydrogel ranged from 551.8-734.2%, the compressive strength ranged from 11.02-102.5 Kpa, and the elastic modulus ranged from 56.73-489.2 Kpa.

[0037] The preparation process of GelMA-HAMA hydrogel is also similar to that of the above-mentioned GelMA hydrogel. On the basis of the prepared GelMA hydrogel, HAMA is added to obtain GelMA-HAMA hydrogel, wherein the ratio of HAMA added is 1-2% (HAMA mg: PBS solution mL). Specifically, GelMA hydrogel prepolymer: PBS solution = 200-300 mg: 2-3 mL; LAP: PBS solution = 4-6 mg: 2-3 mL; HAMA: PBS solution = 20-40 mg: 2-3 mL. The swelling rate and compression strength of the GelMA-HAMA hydrogel were tested respectively, and the results obtained were that the swelling rate of the obtained GelMA-HAMA hydrogel ranged from 642.2-865.3%, the compression strength ranged from 31.35-47.6 Kpa, and the elastic modulus ranged from 124.5-209.9 Kpa.

[0038] (3) Co-culture of GelMA, GelMA-PEGDA and GelMA-HAMA hydrogels with bEnd.3 and MA cells:

[0039] The material toxicity of the three hydrogels, GelMA, GelMA-PEGDA and GelMA-HAMA, was verified by cytotoxicity testing to determine whether they can be co-cultured with cells. Experiments have shown that the three hydrogels, GelMA, GelMA-PEGDA and GelMA-HAMA, used in the present invention have no material toxicity. The survival rate of bEnd.3 and MA cells is as high as 90-150% when cultured in their hydrogel extracts for 1-5 days, and the number of cell proliferation shows a significant upward trend over time. After determining that the three hydrogel materials are non-cytotoxic, the three hydrogels are co-cultured with cells, and the initial amount of two cells co-cultured with the hydrogel is 5×10 5 -4×10 6 cells / mL, and the co-culture time with the hydrogel was 1-5 days. The growth state of the cells on the hydrogel was verified by live and dead cell staining experiments. The hydrogel was stained according to the instructions of the live and dead cell kit on the 1st, 3rd and 5th days respectively, and finally observed by laser confocal instrument, and fluorescence quantitative analysis was performed by ImageJ software, and the calculated cell survival rate was 95-100%.

[0040] The GelMA, GelMA-PEGDA and GelMA-HAMA hydrogels loaded with bEnd.3 and MA cells were placed in a microfluidic chip model, and synthetic blood and artificial cerebrospinal fluid were perfused with a circulating syringe pump to simulate the in vivo blood-brain barrier model. In order to better simulate the in vivo physiological environment, the perfusion and extraction speeds of synthetic blood were 100-300 μL / min, and the perfusion speed of artificial cerebrospinal fluid was 10-20 μL / min.

[0041] (4) Construction and functional verification of microfluidic in vitro blood-brain barrier model:

[0042] The verification of the microfluidic in vitro blood-brain barrier model in the present invention mainly includes the measurement of TEER value and the determination of small molecule permeability. Trans-endothelial electrical resistance (TEER) reflects the ion transfer capacity of the paracellular transport channel. The TEER value can reflect the ability of drugs to pass through the blood-brain barrier and is recognized as the most accurate and sensitive indicator for measuring the integrity of the blood-brain barrier. The present invention uses the Millicell@ERS-2 resistor to perform transendothelial cell electrical impedance detection on the in vitro BBB model. According to the steps in the instruction manual, connect the chopstick electrode to the resistor meter, turn on the resistor meter switch, and let the chopstick electrode stand to stabilize its resistance value. After stabilization, insert the chopstick electrode vertically into the microfluidic chip, place the electrode membrane under the liquid surface, measure the resistance values ​​at different positions three times, and record the resistance value (Ω) on the display screen. Calculate the actual resistance value according to the formula:

[0043] Actual resistance value (Ω·cm 2 ) = (experimental measurement value - blank measurement value) × contact area (cm 2 )

[0044] The tightness of tight junctions is evaluated by measuring the TEER value, and the barrier effect of the BBB in vitro model is assessed. The TEER value of the microfluidic in vitro blood-brain barrier model measured by the present invention ranges from 208.84 to 379.5 Ω·cm 2 Within, see attachment for details Figure 2 .

[0045] Since the main function of BBB is the selective transport of substances, the practical value of the model is evaluated by measuring the permeability of its in vitro model. A high-quality model should have permeability characteristics similar to those in vivo. When evaluating permeability, it is important to choose a suitable molecule. Commonly used tracers include: fluorescein isothiocyanate dextran (FITC-dextran), Evans blue and sodium fluorescein. The present invention uses fluorescein isothiocyanate dextran (FITC-dextran) to measure the penetration of fluorescent tracers in a microfluidic in vitro BBB model to evaluate the selective permeability of the BBB chip.

[0046] Different molecular weights of fluorescein isothiocyanate-dextran (4, 40 and 70 kDa) are often used to investigate the permeability of endothelial cells. The larger the molecular weight, the lower the permeability. The present invention uses 4KDa fluorescein isothiocyanate-dextran to evaluate the permeability of the in vitro microfluidic model. The results are shown in the attached Figure 6. 4KDa FITC-dextran (4kDa, 0.5mg / mL) was continuously pumped into the chip vascular channel at a flow rate of 100-300μL / min using a syringe pump. In order to evaluate and compare the permeability of the microfluidic in vitro BBB model constructed with different cell-laden hydrogels, the fluorescence intensity of the vascular channel was set to 100% for standardization, and then the permeability of the barrier to FITC-dextran was quantified by calculating the ratio of the fluorescence intensity on the brain side to the fluorescence intensity of the vascular channel. The formula is as follows:

[0047]

[0048] Where t represents time, I t Represents the fluorescence intensity of FITC-dextran in the ventricle over time; I v0 represents the maximum value of fluorescence intensity in the vascular channel; V / S represents the ratio of the volume of the vascular channel to its surface area.

[0049] The permeability of 4KDa FITC-dextran measured by the microfluidic in vitro blood-brain barrier model of the present invention is significantly different from that of blank hydrogel. The permeability range of the present invention is 4.851×10 -5 to 4.686×10 -6 cm / s, see attached for details Figure 3 .

[0050] Combined with the TEER values ​​and permeability measurement results of the microfluidic BBB model composed of different cell-loaded hydrogel groups, it is believed that the cell-loaded hydrogel obtained by co-culturing GelMA-5% PEGDA hydrogel with two types of cells is not suitable for the construction of microfluidic BBB model. However, GelMA hydrogels prepared with different feed ratios of MAA: gelatin = 0.1: 1, 0.25: 1, 0.5: 1 (mL: g) can be used for the construction of microfluidic BBB model. Among them, GelMA hydrogel prepared with a feed ratio of MAA: gelatin = 0.25: 1 (mL: g) is most suitable for the construction of microfluidic BBB model, because the BBB model constructed by it has a high TEER value and low permeability of FITC-dextran. For GelMA-PEGDA hydrogel, the permeability of FITC-dextran in the microfluidic BBB model constructed by GelMA-1% PEGDA hydrogel was the lowest among all groups, and the performance of the microfluidic BBB model constructed by GelMA-3% PEGDA hydrogel in TEER value and permeability was at a medium level among all groups. For GelMA-HAMA hydrogel, there was no significant difference in the measured TEER value in the microfluidic BBB model constructed by GelMA-1% HAMA and GelMA-2% HAMA hydrogel, but from the perspective of FITC-dextran permeability, GelMA-2% HAMA hydrogel was better than GelMA-1% HAMA hydrogel.

[0051] Example 1

[0052] A GelMA hydrogel prepolymer with a feed ratio of MA: gelatin = 0.1: 1 (mL: g) was used, mixed with a photoinitiator LAP and a PBS solution with a pH of 7.4 (wherein, GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL), fully dissolved at 37 ° C, and then added to a mold to prepare a hydrogel with a thickness of 3 mm and a diameter of 10 mm. Half of the hydrogel was placed in a vacuum freeze dryer and fully dried for 24 hours, and the initial weight was weighed. It was then placed in a container filled with PBS buffer, taken out at 0.5, 1, 2, 4, 8, and 24 hours, and the excess surface moisture was absorbed with lens paper. It was placed in an analytical balance for weighing, and the sample was tested five times. According to the formula, the swelling rate of GelMA was calculated to be 732.6 ± 2.092%. The other half of the hydrogel was subjected to compression testing at room temperature. The compression test was performed using a universal material testing machine at a speed of 0.6 mm / min until the stress-strain of the hydrogel reached 60%. The sample was tested repeatedly three times, and the compression strength of the hydrogel was obtained to be 18.37±4.142 Kpa, and the elastic modulus was 93.24±21.03 Kpa.

[0053] Example 2

[0054] A GelMA hydrogel prepolymer with a feed ratio of MA: gelatin = 0.25: 1 (mL: g) was used, mixed with a photoinitiator LAP and a PBS solution with a pH of 7.4 (wherein, GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL), fully dissolved at 37°C, and then added to a mold to prepare a hydrogel with a thickness of 3 mm and a diameter of 10 mm. Similar to Example 1, the hydrogel was characterized, and the swelling rate of the hydrogel was 692.5 ± 15.37%, the compressive strength was 39.20 ± 2.163 Kpa, and the elastic modulus was 193.35 ± 35.37 Kpa.

[0055] Example 3

[0056] A GelMA hydrogel prepolymer with a feed ratio of MA: gelatin = 0.35: 1 (mL: g) was used, mixed with a photoinitiator LAP and a PBS solution with a pH of 7.4 (wherein, GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL), fully dissolved at 37°C, and then added to a mold to prepare a hydrogel with a thickness of 3 mm and a diameter of 10 mm. Similar to Example 1, the hydrogel was characterized, and the swelling rate of the hydrogel was 583.2 ± 7.085%, the compressive strength was 52.19 ± 1.657 Kpa, and the elastic modulus was 226.67 ± 34.63 Kpa.

[0057] Example 4

[0058] A GelMA hydrogel prepolymer with a feed ratio of MA: gelatin = 0.45: 1 (mL: g) was used, mixed with a photoinitiator LAP and a PBS solution with a pH of 7.4 (wherein, GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL), fully dissolved at 37°C, and then added to a mold to prepare a hydrogel with a thickness of 3 mm and a diameter of 10 mm. Similar to Example 1, the hydrogel was characterized, and the swelling rate of the hydrogel was 567.9 ± 17.74%, the compressive strength was 64.08 ± 2.438 Kpa, and the elastic modulus was 226.67 ± 34.63 Kpa.

[0059] Example 5

[0060] A GelMA hydrogel prepolymer with a feed ratio of MA: gelatin = 0.5: 1 (mL: g) was used, mixed with a photoinitiator LAP and a PBS solution with a pH of 7.4 (wherein, GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL), fully dissolved at 37°C, and then added to a mold to prepare a hydrogel with a thickness of 3 mm and a diameter of 10 mm. Similar to Example 1, the hydrogel was characterized, and the swelling rate of the hydrogel was 473.8 ± 23.47%, the compressive strength was 76.99 ± 5.731 Kpa, and the elastic modulus was 434.80 ± 90.77 Kpa.

[0061] Example 6

[0062] PEGDA was added to the GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1: 1 (mL: g), and mixed with the photoinitiator LAP and a PBS solution with a pH of 7.4, and fully dissolved at 37°C. GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL; PEGDA: PBS solution = 20-100 mg: 2 mL. After dissolution, it was added to a mold to prepare a hydrogel with a thickness of 3 mm and a diameter of 10 mm. Similar to Example 1, the hydrogel was characterized, and the swelling rate of the hydrogel was 551.8%-734.2%, the compressive strength was 11.02 Kpa-102.5 Kpa, and the elastic modulus was 56.73 Kpa-489.2 Kpa.

[0063] Example 7

[0064] HAMA was added to the GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g), and mixed with the photoinitiator LAP and a PBS solution with a pH of 7.4, and fully dissolved at 37°C. GelMA hydrogel prepolymer: PBS solution = 200mg:2mL; LAP: PBS solution = 4mg:2mL; HAMA: PBS solution = 10-20mg:2mL. After dissolution, it was added to a mold to prepare a hydrogel with a thickness of 3mm and a diameter of 10mm. Similar to Example 1, the hydrogel was characterized, and the swelling rate of the hydrogel was 642.2-865.3%, the compressive strength was 31.35Kpa-47.50Kpa, and the elastic modulus was 124.5-209.9Kpa.

[0065] Example 8

[0066] Six GelMA hydrogel sheets with a thickness of 1 mm and 2 mm, a length of 14 mm, and a width of 3 mm were prepared with a feed ratio of MAA: gelatin = 0.1:1 (mL:g). They were co-cultured with mouse brain microvascular endothelial cells (bEnd.3) and mouse astrocytes (MA). The initial cell seeding density was 2×10 5 cells / mL, and the culture time was 5 days. After 5 days, 6 hydrogel sheets loaded with mouse brain microvascular endothelial cells (bEnd.3) (3 sheets with 1 mm and 3 sheets with 2 mm) and 6 hydrogel sheets loaded with mouse astrocytes (MA) (3 sheets with 1 mm and 3 sheets with 2 mm) were obtained. The cell survival rates of the hydrogels loaded with mouse brain microvascular endothelial cells (bEnd.3) and the hydrogels loaded with mouse astrocytes (MA) were both higher than 95%, see attached Figure 4 . The hydrogel sheet was placed in a specific groove of the microfluidic BBB chip, wherein the hydrogel sheet carrying mouse brain microvascular endothelial cells (bEnd.3) was placed on the side close to the blood channel, and the hydrogel sheet carrying mouse astrocytes (MA) was placed on the side of the cerebrospinal fluid channel. Artificial synthetic blood and artificial cerebrospinal fluid were introduced into the microfluidic BBB chip model using a circulating injection pump, wherein the flow rate of the artificial synthetic blood was 150 μL / min, and the flow rate of the artificial cerebrospinal fluid was 10 μL / min. The timing was started after the fluid circulation of the microfluidic BBB model was formed. After the fluid of the microfluidic blood-brain barrier model circulated for 3 hours, the TEER value was measured to be 236.9 Ω·cm 2 FITC-dextran was then introduced into the blood channel of the model. After 4 hours, the permeability was measured according to the method mentioned in the above invention content and was 7.412×10 -6 cm / s.

[0067] Example 9

[0068] The feed ratio of MAA: gelatin = 0.1:1 (mL:g) in Example 8 was changed to MA: gelatin = 0.25:1 (mL:g) to prepare GelMA hydrogel sheets with thickness of 1mm and 2mm, and the other conditions remained unchanged. The cell survival rates of the hydrogels loaded with mouse brain microvascular endothelial cells (bEnd.3) and the hydrogels loaded with mouse astrocytes (MA) were both higher than 98%, see attached Figure 4 The steps of TEER value and permeability test were the same as those in Example 9, and the TEER value was 293.2Ω·cm 2 , the permeability is 4.257×10 -6 cm / s.

[0069] Example 10

[0070] The feed ratio of MAA: gelatin = 0.1:1 (mL:g) in Example 8 was changed to MA: gelatin = 0.5:1 (mL:g) to prepare GelMA hydrogel sheets with thickness of 1mm and 2mm, and the other conditions remained unchanged. The cell survival rates of the hydrogels loaded with mouse brain microvascular endothelial cells (bEnd.3) and the hydrogels loaded with mouse astrocytes (MA) were both higher than 98%, see attached Figure 4 The steps of TEER value and permeability test were the same as those in Example 9, and the TEER value was 240.2Ω·cm 2 , the permeability is 1.563×10 -5 cm / s.

[0071] Example 11

[0072] PEGDA was added to the GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g), wherein GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL; PEGDA: PBS solution = 20 mg: 2 mL. Six GelMA-PEGDA hydrogel sheets with a thickness of 1 mm and 2 mm, a length of 14 mm, and a width of 3 mm were co-cultured with mouse brain microvascular endothelial cells (bEnd.3) and mouse astrocytes (MA), and the initial cell seeding density was 2×10 5 cells / mL, and the culture time was 5 days. After 5 days, 6 hydrogel sheets loaded with mouse brain microvascular endothelial cells (bEnd.3) (3 sheets with 1 mm and 3 sheets with 2 mm) and 6 hydrogel sheets loaded with mouse astrocytes (MA) (3 sheets with 1 mm and 3 sheets with 2 mm) were obtained. The cell survival rates of the hydrogels loaded with mouse brain microvascular endothelial cells (bEnd.3) and the hydrogels loaded with mouse astrocytes (MA) were both higher than 95%, see attached Figure 5 The steps of TEER value and permeability test were the same as those in Example 8, and the TEER value was 342.2Ω·cm 2 , the permeability is 4.686×10 -6 cm / s.

[0073] Example 12

[0074] PEGDA was added to the GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g), and mixed with the photoinitiator LAP and a PBS solution with a pH of 7.4, and fully dissolved at 37°C. GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL; PEGDA: PBS solution = 60.6 mg: 2 mL. The preparation of the hydrogel sheet and its cell culture process were the same as in Example 11. The cell survival rates of the obtained hydrogel containing mouse brain microvascular endothelial cells (bEnd.3) and the hydrogel containing mouse astrocytes (MA) were both higher than 95%, see attached. Figure 5 The steps of TEER value and permeability test were the same as those in Example 8, and the TEER value was 379.5Ω·cm 2 , the permeability is 2.791×10 -5 cm / s.

[0075] Example 13

[0076] PEGDA was added to the GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g), and mixed with the photoinitiator LAP and a PBS solution with a pH of 7.4, and fully dissolved at 37°C. GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL; PEGDA: PBS solution = 100 mg: 2 mL. The preparation of the hydrogel sheet and its cell culture process were the same as in Example 11. The cell survival rates of the obtained hydrogels loaded with mouse brain microvascular endothelial cells (bEnd.3) and the hydrogels loaded with mouse astrocytes (MA) were both higher than 98%, see attached. Figure 5 The steps of TEER value and permeability test were the same as those in Example 8, and the TEER value was 208.8Ω·cm 2 , the permeability is 4.531×10 -5 cm / s.

[0077] Example 14

[0078] HAMA was added to the GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g), and mixed with the photoinitiator LAP and a PBS solution with a pH of 7.4, and fully dissolved at 37°C. GelMA hydrogel prepolymer: PBS solution = 200 mg: 2 mL; LAP: PBS solution = 4 mg: 2 mL; HAMA: PBS solution = 20 mg: 2 mL. The preparation of the hydrogel sheet and its cell culture process were the same as in Example 11, and the cell survival rates of the hydrogel containing mouse brain microvascular endothelial cells (bEnd.3) and the hydrogel containing mouse astrocytes (MA) were both higher than 98%, see attached. Figure 6 The steps of TEER value and permeability test were the same as those in Example 8, and the TEER value was 320.2Ω·cm 2 , the permeability is 2.709×10 -5 cm / s.

[0079] Example 15

[0080] HAMA was added to the GelMA hydrogel prepolymer with a feed ratio of MAA: gelatin = 0.1:1 (mL:g), and mixed with the photoinitiator LAP and a PBS solution with a pH of 7.4, and fully dissolved at 37°C. GelMA hydrogel prepolymer: PBS solution = 200mg:2mL; LAP: PBS solution = 4mg:2mL; HAMA: PBS solution = 40mg:2mL. The preparation of the hydrogel sheet and its cell culture process were the same as in Example 11, and the cell survival rates of the hydrogel containing mouse brain microvascular endothelial cells (bEnd.3) and the hydrogel containing mouse astrocytes (MA) were both higher than 98%, see attached. Figure 6 The steps of TEER value and permeability test were the same as those in Example 8, and the TEER value was 323.8Ω·cm 2 , the permeability is 1.822×10 -5 cm / s.

Claims

1. A microfluidic in vitro blood-brain barrier model, characterized in that: include: A microfluidic chip, a glass bottom plate, a hydrogel and a microinjection circulation pump; the microfluidic chip is arranged on the glass bottom plate, the microfluidic chip comprises a first channel, a second channel and a third channel, the channels are separated by a first PDMS column and a second PDMS column; the microfluidic chip is separated by a PDMS separation column and is divided into three parts with the same structure; the hydrogel comprises a hydrogel carrying mouse brain microvascular endothelial cells and a hydrogel carrying mouse astrocytes; the microinjection circulation pump is used for perfusing artificial cerebrospinal fluid and artificial synthetic blood that simulate the blood-brain barrier in vivo.

2. A microfluidic in vitro blood-brain barrier model according to claim 1, characterized in that: The hydrogel carrying mouse brain microvascular endothelial cells includes GelMA, GelMA-PEGDA, and GelMA-HAMA hydrogels carrying mouse brain microvascular endothelial cells; the mouse astrocytes carrying mouse astrocytes include GelMA, GelMA-PEGDA, and GelMA-HAMA hydrogels carrying mouse astrocytes.

3. A microfluidic in vitro blood-brain barrier model according to claim 2, characterized in that: The hydrogels are all synthesized by ultraviolet light curing and cross-linking, the light curing time is 5-10 minutes, the photoinitiators are Irgacure2959 and LAP, the concentration of the photoinitiator is 0.2%-0.5%, the illumination time is 5-10 minutes, the illumination height is 5-20 cm, and finally the thickness of the obtained hydrogel sheet is controlled to be 1-2 mm; wherein, the ultraviolet light curing band is 405 nm, the ultraviolet lamp power is 20-30 W, and the concentration of the photoinitiator is: photoinitiator mg / PBS solution mL.

4. A microfluidic in vitro blood-brain barrier model according to claim 3, characterized in that: The GelMA, GelMA-PEGDA and GelMA-HAMA hydrogels are prepared by the following method: GelMA hydrogels were prepared by using different feed ratios of MAA: gelatin = 0.1-0.5 mL: 1 g according to the different grafting of methacrylic anhydride MAA. The MAA grafting rate of the obtained hydrogels ranged from 50.5% to 68%. The swelling rate of GelMA hydrogels with different grafting rates ranged from 473.8% to 732.6%, the compressive strength ranged from 15.37% to 76.99 KPa, and the elastic modulus ranged from 93.24% to 434.8 KPa. In the GelMA precursor material, PEGDA is added to obtain a GelMA-PEGDA hydrogel, wherein the proportion of PEGDA added is 1-5%, and the proportion is PEGDAg / PBS solution mL; the swelling rate of the GelMA-PEGDA hydrogel ranges from 551.8 to 734.2%, the compressive strength ranges from 11.02 to 102.5 KPa, and the elastic modulus ranges from 56.73 to 489.2 KPa; By adding HAMA to the GelMA precursor material, GelMA-HAMA hydrogel is obtained, wherein the proportion of HAMA added is 1-2%, and the ratio is HAMAg / PBS solution mL; the swelling rate of GelMA-HAMA hydrogel ranges from 642.2-865.3%, the compression strength ranges from 31.35-47.6Kpa, and the elastic modulus ranges from 124.5-209.9Kpa.

5. The microfluidic in vitro blood-brain barrier model according to claim 1, characterized in that: The microfluidic chip package is divided into a first channel, a second channel and a third channel in sequence; the first channel is used for perfusing cerebrospinal fluid, the second channel is used for placing a cell-carrying hydrogel sheet, and the third channel is used for perfusing artificial synthetic blood; the second channel is provided with a groove for fixing the hydrogel sheet, and the groove is separated by a first PDMS column and a second PDMS column, dividing the groove into two parts; the hydrogel carrying mouse brain microvascular endothelial cells is placed in the groove close to the third channel, and the hydrogel carrying mouse astrocytes is placed in the groove close to the first channel.

6. A microfluidic in vitro blood-brain barrier model according to claim 5, characterized in that: The glass base plate is 64 mm long, 34 mm wide and 4 mm high; the chip is 46 mm long, 24 mm wide and 6 mm high; the first PDMS column is 2.4 mm long, 1 mm wide, with a spacing of 0.3 mm and a height of 3 mm; the second PDMS column is 0.3 mm long, 1 mm wide and 1 mm high; the first channel is 46 mm long, 6.5 mm wide and 4 mm deep; the two parts of the second channel groove are the same, 14 mm long, 3 mm wide and 3 mm high; the third channel is 46 mm long, 8.5 mm wide and 4 mm deep; the PDMS separator column is 15.9 mm long, 6.5 mm wide and 2.8 mm high.

7. The method for using the microfluidic in vitro blood-brain barrier model according to any one of claims 1 to 6, characterized in that: The steps include: GelMA, GelMA-PEGDA, and GelMA-HAMA hydrogels were co-cultured with mouse brain microvascular endothelial cell hydrogels and astrocytes; the initial amount of the two cells co-cultured with the hydrogels was 5×10 5 -4×10 6 cells / mL, and the co-culture time of the two cells with the hydrogel was 1-5 days; The hydrogels carrying mouse brain microvascular endothelial cells and the hydrogels carrying astrocytes are placed in corresponding hydrogel channels; when the hydrogel sheets form a microfluidic BBB model, the same type of hydrogel sheets are selected to place the hydrogel sheets carrying mouse brain microvascular endothelial cells and the hydrogel sheets carrying astrocytes, or two different types of hydrogel sheets are selected to place the hydrogel sheets carrying mouse brain microvascular endothelial cells and the hydrogel sheets carrying astrocytes; Use a microinjection circulation pump to introduce artificial synthetic blood at a flow rate of 100-300 μL / min, and artificial cerebrospinal fluid at a flow rate of 10-20 μL / min; After the artificial synthetic blood and artificial cerebrospinal fluid circulate in the microfluidic chip for 3-5 hours, the TEER value is measured; 4KDa FITC-dextran is introduced into the synthetic blood channel, and the fluorescence intensity of the blood channel and the artificial cerebrospinal fluid channel is measured 4-5 hours later to verify the permeability of FITC-dextran.

Citation Information

Cited By

  • Micro-fluidic brain organ chip as well as construction method and application thereof

    CN119752625A

  • Microfluidic brain organ chip, construction method and application thereof

    CN119752625B

  • Construction method and application of three-dimensional in-vitro blood brain barrier model with barrier function

    CN120555328A

  • A method for constructing a three-dimensional in vitro blood-brain barrier model with barrier function and its application

    CN120555328B